Wolverine Trading’s ImmunityBio IBRX Stock Holding History

Wolverine Trading’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$81.3K	Buy	31,631 +8,838	+39%	+$22.8K	﹤0.01%	5276
2025 Q2	$61.5K	Buy	+22,793	New	+$61.3K	﹤0.01%	4296
2024 Q2	–	Sell	-13,303	Closed	-$71.4K	–	4814
2024 Q1	$71.4K	Buy	+13,303	New	+$60.2K	﹤0.01%	4135
2023 Q3	–	Sell	-32,178	Closed	-$64.6K	–	4764
2023 Q2	$87.5K	Buy	32,178 +11,891	+59%	+$33.6K	﹤0.01%	3818
2023 Q1	$36K	Buy	+20,287	New	+$63.1K	﹤0.01%	3896
2022 Q2	–	Sell	-26,082	Closed	-$105K	–	5060
2022 Q1	$154K	Buy	+26,082	New	+$160K	﹤0.01%	4586
2021 Q2	–	Sell	-36,650	Closed	-$605K	–	6312
2021 Q1	$870K	Sell	36,650 -666	-2%	-$17.3K	﹤0.01%	2936
2020 Q4	$536K	Buy	+37,316	New	+$359K	﹤0.01%	3088
2020 Q1	–	Sell	-11,633	Closed	-$58.3K	–	4902
2019 Q4	$45K	Buy	+11,633	New	+$19.8K	﹤0.01%	4478

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Wolverine Trading's IBRX Position: Q3 2025 in Review

Wolverine Trading increased its ImmunityBio (IBRX) stake by 39% in Q3 2025, buying an estimated $22.8K and bringing the position to 31,631 shares worth $81.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5276.

Wolverine Trading first reported a position in IBRX in Q4 2019 and has held it in 9 quarters since. The position peaked at $870K in Q1 2021. 264 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

Wolverine Trading held 31,631 shares of ImmunityBio worth $81.3K as of Q3 2025.
Wolverine Trading bought 8,838 ImmunityBio shares in Q3 2025, an estimated $22.8K.
ImmunityBio made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5276 holding.
Wolverine Trading first reported a position in ImmunityBio in Q4 2019 and has held it in 9 quarters since.
Wolverine Trading's ImmunityBio position peaked at $870K in Q1 2021.
264 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.